TEVERELIX
Advanced Prostate Cancer
Antev Ltd.protein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the Advanced Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
qlc5508 Qilu Pharmaceutical Co., Ltd. | Phase 3 | B |
Fluciclovine Brigham and Women's Hospital | Phase 2 | B |
hs-20093 Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | B |
Dkf-Ma102 Dongkook Pharmaceutical Co., Ltd. | Phase 3 | B |
Nivolumab Parker Institute for Cancer Immunotherapy | Phase 2 | B |
View all 21 →
Same molecule, other indications
TEVERELIX is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →